相关实验视频
Updated: Jul 20, 2025

06:08
Quantification of Hypopigmentation Activity In Vitro
Published on: March 6, 2019
11.4K
作为黑色素瘤生长抑制剂的花
Annette M Mathew1, Zuliang Deng2, Christian J Nelson3
1The Department of Microbiology & Immunology, Des Moines University College of Osteopathic Medicine, Des Moines, IA, 50312, USA.
Medical oncology (Northwood, London, England)
|August 6, 2023
概括
提取物 (AE) 通过减少细胞增殖和促进细胞亡,有效地抑制黑色素瘤的生长. 这项研究表明,AE可能是黑色素瘤的有希望的自然治疗方法.
科学领域:
- 在瘤学瘤学.
- 植物化学 植物化学
- 分子生物学分子生物学
背景情况:
- 黑色素瘤是一种致命的皮肤癌,发病率越来越高.
- 菜提取物 (AE) 具有抗癌特性,可以对抗各种癌症.
- AE对黑色素瘤的影响在很大程度上仍未被探索.
研究的目的:
- 为了研究桃提取物 (AE) 对黑色素瘤细胞生长的直接影响.
- 阐明AE对黑色素瘤细胞影响的分子机制.
主要方法:
- 使用了克隆基因生存试验,细胞增殖试验和caspase-3活动套件.
- 在HTB-72黑色素瘤细胞系上使用RT-PCR和免疫组织化学染色来评估分子变化.
- 研究了参与细胞周期调节和细胞亡的关键蛋白质的表达.
主要成果:
- AE显著降低了黑色素瘤殖民地形成和细胞活力 (OD值降低).
- AE治疗导致PCNA mRNA表达率下降,表明增殖减少.
- AE增加了酶-3活性并促进了亡,由改变的p21,p27,CDK4和幸存者水平证明.
结论:
- 菜提取物对黑色素瘤细胞表现出显著的抗增殖和促亡作用.
- AE通过涉及细胞周期调节和亡诱导的机制抑制黑色素瘤的生长.
- 花提取物具有作为新治疗黑色素瘤治疗的新疗剂的潜力.
相关概念视频
Skin Cancer
4.2K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
4.2K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Tumor Progression
6.4K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.4K
Tumor Immunotherapy
557
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
557
Regulation of Angiogenesis and Blood Supply
2.6K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K

